Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 601–700 of 856
Koca, S., Kiris, İ., Şahin, Ş., Karşıdağ, S., Çınar, N., & Baykal, A. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-22783-9 · Cited by 5
“These alterations may be mediated by systemic inflammation, circulating amyloid-beta, or genetic risk factors such as APOE4 50,51 .”
Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease
Ward, K., Cole, M. H., Griffiths, L. R., Sutherland, H. G. E., Winberg, P. C., Meyer, B. J., & Fernandez, F. (2025) · Molecules · doi:10.3390/molecules30224456 · Cited by 4
“…damaged with ageing, impairing respiratory chain function and producing defective electron transport complexes that leak electrons and perpetuating ROS formation, establishing a self-reinforcing cycle of mitochondrial dysfunction and oxidative stress (see orange pathway in Figure 1) [81,82].”
Zhang, X., Yang, J., Meng, X., Zhang, J., Cai, C., Wei, W., Fang, S., Ren, X., Guo, K., Yang, P., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157602 · Cited by 3
A blood based mitochondrial functional index biomarker for Alzheimer's disease
Hauger, B. M., Kemna, R. E., Kueck, P. J., Strope, T. A., John, C. S., Smith, K. P., Mayfield, H. D., Herrold, E., Cox, K., Bothwell, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71061 · Cited by 5
“21,28 Mitochondrial dysfunction plays a role in protein aggregation, inflammation, and cell death – all events observed in AD.”
Self-citationFacchinetti, R., Valenza, M., Ciarla, C., Steardo, L., Serviddio, G., Palombelli, G., Verkhratsky, A., Steardo, L., Canese, R., Cassano, T., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118965 · Cited by 3
From Lipids to Mitochondria: Shared Metabolic Alterations in Obesity and Alzheimer’s Disease
Uranga, R. M., & Allani, S. K. (2026) · Cells · doi:10.3390/cells15080672 · Cited by 3
“The mitochondrial cascade hypothesis, first proposed by Swerdlow and Khan (2004), provides a unifying framework for AD pathology, suggesting that mitochondrial dysfunction precedes A β deposition, tau phosphorylation, and neurodegeneration [97,98].”
The multifaceted role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis
Ebrahimi, R., Mohammadi, I., Ghafourian, K., Firouzabadi, S. R., Saleh, M., Davoody, S., Azad, G., & Esmaeilpour, K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01850-8 · Cited by 4
Khan, M. S. H., Hefner, M., Reddy, A. P., Dhurandhar, N. V., & Hegde, V. K. (2023) · Nutrition and Diabetes · doi:10.1038/s41387-023-00242-6 · Cited by 3
“Studies have shown extensive mitochondria abnormalities in the brain of AD patients [33] and mitochondrial dysfunction has been established as an early and prominent feature of AD [33, 34].”
Flavonoid-Based Derivatives for Modulating Various Targets of Alzheimer’s Disease
Pandey, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_11 · Cited by 4
Marine-derived Compounds: A Powerful Platform for the Treatment of Alzheimer’s Disease
Arora, R., Babbar, R., Dabra, A., Chopra, B., Deswal, G., & Grewal, A. S. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249269050231129103002 · Cited by 6
Zhu, Y., Liao, L., Gao, S.-H., Tao, Y. K., Huang, H., Fang, X., Yuan, C., & Gao, C.-Y. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.40 · Cited by 4
“138 Speci fi cally, the inhibition of mitochondrial respiration can promote the amyloidosis process of APP, and consequently, induce the overproduction of A β .”
Wang, M., & Liu, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-58584-9 · Cited by 5
Inflammation in the pathogenesis of neurodegenerative diseases
Гончаров, А. Г., Reverchuk, I. V., & Shupletsova, V. V. (2023) · Cytokines and inflammation · doi:10.17816/ci627304 · Cited by 4
GluN2B of NMDA Receptor and Calmodulin: Balanced Calcium Regulation to Combat Alzheimer's Disease
Tiwari, P. K., Kadiri, S. K., Khobragade, D. S., & Dubey, S. (2025) · Current Drug Therapy · doi:10.2174/0115748855341835250120064444 · Cited by 4
Luo, Q., Ye, X., Xu, J., Sun, Z., Wang, P., Chen, H., Gao, T., Deng, Q., Wang, Z., Wang, Q., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01814-y · Cited by 3
“However, the Q10 level in the human were gradually decline from 35-year-olds [46], Especially, AD patients present lower serum levels of Q10 [47, 48], and mitochondrial dysfunction is associated with pathological changes in AD [49, 50].”
Mitochondrial Dysfunction in Neurodegenerative Diseases
Chen, C., Zhao, Y., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Lu, M., et al. (2025) · MedComm · doi:10.1002/mco2.70326 · Cited by 4
“In contrast, the mitochondrial cascade hypothesis suggests that inherited mitochondrial function and its decline over time play a primary role in the disease’s pathogenesis, potentially influencing A β accumulation [138, 139].”
Camins, A., Ettcheto, M., & Busquets, O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257513 · Cited by 3
“…however, other mechanisms are involved in this process such as the production of reactive oxygen species in the mitochondria, the activation of the unfolded protein response in the endoplasmic reticulum and the upregulation of proinflammatory responses (Cummings et al., 2018; Swerdlow 2018).”
BackgroundXiao, X., Wei, J., Zhang, W., Jiao, B., Liao, X., Pan, C., Liu, X., Yan, X., Tang, B., Zhang, Y., et al. (2019) · Neuroreport · doi:10.1097/wnr.0000000000001297 · Cited by 3
Mitochondria as a toxicological target for fungicides
Silva, M. G., Mendes, D., Oliveira, M. M., Andrade, P. B., Videira, R. A., & Peixoto, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88462-4.00012-2 · Cited by 5
Kaur, K. K., Allahbadia, G., & Singh, M. (2021) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2021.08.00228 · Cited by 6
Barnes, J. N., Burns, J. M., Bamman, M. M., Billinger, S. A., Bodine, S. C., Booth, F. W., Brassard, P., Clemons, T. A., Fadel, P. J., Geiger, P. C., et al. (2022) · Brain Plasticity · doi:10.3233/bpl-220146 · Cited by 4
“In the brains of AD patients, mitochondria have structural and functional deficits [80] and mitochondrial dysfunction may further AD pathology [81].”
BackgroundSelf-citationTrehalose improves the movement ability of Aβarc Drosophila by restoring the damaged mitochondria
Li, L., Huang, Z., Wu, M., Li, X., Xiao, B., Dong, Y., & Mo, B. (2024) · Translational Neuroscience · doi:10.1515/tnsci-2022-0338 · Cited by 3
“Moreover, mitochondrial cascade hypothesis proposes that mitochondrial dysfunction drive the pathogenesis of AD [34].”
BackgroundStereotactic surgery and its application in Alzheimer’s disease rat models
Tekin, E. (2024) · Journal of Surgery and Medicine · doi:10.28982/josam.7643 · Cited by 3
“…deterioration in both synaptic plasticity and long-term potentiation, pericyte dysfunction, metal dyshomeostasis, mitochondrial distress, blood–brain barrier P a g e | 2 dysfunction, and pathologies associated with tau hyperphosphorylation, have been described in the development of AD [23–26].”
BackgroundStructural basis of bioenergetic protein complexes in Alzheimer's disease pathogenesis
McGregor, L., & Soler‐López, M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102573 · Cited by 4
Measurement of Oxygen Consumption Rate in Acute Striatal Slices from Adult Mice
Zhi, L., Zhao, J., Jaffe, D. E., Chen, Y., Wang, N., Qin, Q., Seifert, E. L., Li, C., & Zhang, H. (2022) · Journal of Visualized Experiments · doi:10.3791/63379 · Cited by 3
Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological diseasePreprint
Larsen, P. A., Hunnicutt, K. E., Larsen, R. J., Yoder, A. D., & Saunders, A. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/230367 · Cited by 2
Editorial: Metabolism in Alzheimer's Disease
Morris, J. K., Wood, L. B., & Wilkins, H. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.824145 · Cited by 3
“…in brain glucose metabolism, mitochondrial dysfunction is observed not only within the brain but also systemically (Parker, 1991; Kish et al., 1992; Cardoso et al., 2004a,b; Morris et al., 2014b; Fisar et al., 2016; Guo et al., 2017; Swerdlow, 2018; Baloyannis, 2019; Chakravorty et al., 2019).”
BackgroundMitochondrial double-stranded RNA accumulation in brain aging and Alzheimer’s diseasePreprint
Doser, R. L., & LaRocca, T. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703345 · Cited by 3
“Among the cellular hallmarks of aging and AD, mitochondrial dysfunction is especially prominent and encompasses impairments in mitochondrial metabolism, proteostasis, and quality control mechanisms such as fission, fusion, mitophagy, and biogenesis 2–4 .”
Stefano, G. B., Büttiker, P., Weissenberger, S., Raboch, J., & Anders, M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101217 · Cited by 4
Oleanolic Acid and Alzheimer’s Disease: Mechanistic Hypothesis of Therapeutic Potential
Espinosa-Cabello, J. M., Fernández‐Aparicio, Á., González‐Jiménez, E., Perez-Muñoz, G., Castellano, J. M., & Perona, J. S. (2026) · Applied Sciences · doi:10.3390/app16010494 · Cited by 2
Bossardet, O. L., Clark, K. L., Wade, S., Snyder, L. A., Mecca, S., Holden, J. M., Almaoui, E., Konety, R., Ghanem, G. O. B., Korobkina, E. D., et al. (2026) · Scientific Reports · doi:10.1038/s41598-025-34243-5 · Cited by 3
Pahal, S., Ganne, A., Balasubramaniam, M., Griffin, S. T., Reis, R. J. S., & Ayyadevara, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1713391 · Cited by 3
“Mitochondrial impairment is a hallmark of both normal aging of the brain (Sutherland et al., 2021) and age-associated cognitive decline in AD (Esselun et al., 2021; Swerdlow, 2017).”
Zhai, Y., Nevian, T., Finn, D. P., & Kwakowsky, A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00025-0 · Cited by 2
Resveratrol induces molecular changes in cholesterol homeostasis in SAMP8 mice cerebellum
Tejero, A., Benito-Patón, V., Griñán‐Ferré, C., Pallàs, M., León-Navarro, D., & Martín, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119319 · Cited by 2
Mitochondrial dysfunction in sleep deprivation
Zhao, M., Abbasi, A. A., Li, P., & Lu, P. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01853-5 · Cited by 2
Yılmaz, A., Park, H.-J., Ahn, E., & Bae, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093930 · Cited by 5
“From a disease-mechanism perspective, this pleiotropy may be particularly useful in Alzheimer’s disease, where amyloid burden alone does not explain the full extent of synaptic failure and cognitive decline [157–159].”
InfluentialYadav, B., Gangwar, P., Kumari, K., Yadav, A., Rao, R., Kumar, K., Verma, H., Dhiman, M., & Mantha, A. K. (2026) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2026.1835778 · Cited by 3
Hernández-Contreras, K. A., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., Rojas-Durán, F., & Aranda-Abreu, G. E. (2021) · Revista de Fomento Social · doi:10.24875/rmn.20000087 · Cited by 4
Natural products regulate mitochondrial function in cognitive dysfunction—A scoping review
Tuo, J., Peng, Y., Linghu, Y., Ming, T., Huang, S., & Xu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1091879 · Cited by 2
“The accumulation of damaged mitochondria further accelerates the progression of cognitive dysfunction (Swerdlow, 2018).”
BackgroundHu, Y., Xing, S., Huang, Y., Chen, C., Shen, D., & Chen, J. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230428112358 · Cited by 2
Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Ciceri, D., Gregorio-Zabala, L., Llama-Pino, X., Kurt, B., Olano-Bringas, J., Villegas‐Zafra, P., & Bengoa‐Vergniory, N. (2023) · Journal of Visualized Experiments · doi:10.3791/65453 · Cited by 2
Ng, E. L., Reed, A. L., O’Connell, C. B., & Alder, N. N. (2023) · Journal of Visualized Experiments · doi:10.3791/65561 · Cited by 4
Li, Z., Lin, H.-S., Huang, X.-P., Zhang, S.-Q. Y., Shu, X., & Wu, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.04 · Cited by 4
Promising Prospects for Human Cerebral Organoids to Advance Alzheimer's Disease Research
López, V., Rosca, A., Liste, I., Mateos-Martínez, P., Coronel, R., González-Sastre, R., Martín-Benito, S., & López, V. (2023) · Progress in Neurobiology · doi:10.60124/j.pneuro.2023.20.05 · Cited by 1
Regulation of mitochondrial function by FOXOs in ischemic stroke and Alzheimer’s disease
Asadi, Y., & Wang, H. (2024) · Organelle · doi:10.61747/0ifp.202403001 · Cited by 2
Tsai, T. H., Wu, C. Y., Chang, C., Lin, T., Liu, C., & Chen, P. S. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12914 · Cited by 2
Zheng, W., Lin, D., Shi, S., Ren, J., Wu, J., Wang, M., & Wan, S. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241289804 · Cited by 4
“43,44 Key features of this dysfunction include abnormalities in mitochondrial fi ssion and fusion, impaired function of mitochondria-associated membranes, insuf fi cient mitophagy, and disrupted protein homeostasis.”
Hoga, K., Wakuzawa, M., Nakamura, T., Kato, Y., & Fukui, K. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.24-122 · Cited by 2
“(37,38) As neurite degeneration also occurs in these diseases, (15,16) our results may serve as a good model for future studies.”
Соколик, Е. П., & Prozorova, G. O. (2022) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v5i3.151 · Cited by 2
Alzheimer’s Disease—Molecular Defect, Public Perceptions and Stigma in South Africa
Maduna, T., & Loos, B. (2021) · Springer eBooks · doi:10.1007/978-981-16-2546-6_4 · Cited by 4
Olaniran, A. F., Taiwo, A. E., Alike-Peter, M. E., Okonkwo, C. E., Sanusi, A., Olaniran, O. D., & Erinle, O. C. (2023) · International Conference on Science, Engineering and Business for Sustainable Development Goals (SEB-SDG) · doi:10.1109/seb-sdg57117.2023.10124581 · Cited by 2
Raheem, H. A., Albazi, W. J., Altaee, R., AL-Thuwaini, T. M., & Jhoni, G. H. (2023) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2023.139742.2973 · Cited by 4
“Intracellular A can alter mitochondrial function and promote the generation of ROS, which is further exacerbated by cholesterol-mediated depletion of mitochondrial glutathione (GSH) (19,27).”
BackgroundElder, M. K., Erdjument‐Bromage, H., Oliveira, M. M., Mamcarz, M., Neubert, T. A., & Klann, E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.21.260786 · Cited by 2
“, 2001), but whether 320 these deficits contribute to the disease or whether they are a biproduct of disease progression 321 continues to be debated (Swerdlow, 2018).”
BackgroundChacko, L., Nag, S., Dewanjee, S., Ghosh, S., Vallamkondu, J., Mitra, O., Dey, A., Bhuniya, T., Paluru, H. P. R., Reddy, P. H., et al. (2022) · Preprints.org · doi:10.20944/preprints202211.0032.v1 · Cited by 2
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.16.523715 · Cited by 2
Profiling of the Proteins Interacting with Amyloid Beta Peptides in Clinical Samples by PACTS-TPP
Xu, M., Wang, X., Zhang, Y., Ji, N., Wang, Q., Zhao, T., Zhou, C., & Jia, C. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00083 · Cited by 2
Alzheimer’s Disease: Cellular and Pharmacological Aspects
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., Chi-Castañeda, D., Toledo‐Cárdenas, M. R., & Suárez-Medellín, J. M. (2024) · Geriatrics · doi:10.3390/geriatrics9040086 · Cited by 2
“The mitochondrial membrane may be affected by the action of amyloid and Tau peptides, resulting in mitochondrial dysfunction causing primarily bioenergetic and respiratory chain failure [61]; moreover, mitochondria associated with the endoplasmic reticulum may also be affected [62].”
Age-related hearing loss: possible associations with Alzheimer’s disease
Ma, Y., Yang, Y., Zhou, Y.-F., Le, W., & Chai, R. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.24 · Cited by 1
Stoškuvienė, A., Chaleckas, E., Grušauskienė, E., Bartušis, L., Celikkaya, G., Janulevičienė, I., Vaitkus, A., Ragauskas, A., & Hamarat, Y. (2025) · Medicina · doi:10.3390/medicina61060972 · Cited by 2
“Both conditions are associated with impaired blood flow and increased oxidative stress, which contribute to neurodegeneration [6,29].”
Pacheco-Sánchez, B., Verheul-Campos, J., Vargas, A., Tovar, R., Rodríguez-Pozo, M., Navarro, J. A., López-Gambero, A. J., Baixerás, E., Serrano-Castro, P. J., Suárez, J., et al. (2025) · Nutrients · doi:10.3390/nu17183024 · Cited by 2
“Such defects might compromise ATP synthesis, elevate reactive oxygen species (ROS) production, and disrupt calcium buffering, leading to oxidative stress and increased vulnerability to intrinsic apoptosis [33,34].”
Kim, J.-S., & Cho, H. (2025) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2025.31.3.236 · Cited by 1
Wu, K.-C., Lin, C., Tran, T., Lin, J., Yeh, H., Ho, C., Chern, Y., & Lin, C. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70176 · Cited by 3
Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1
“In AD, mitochondrial dysfunction promotes the accumulation of p-Tau and Aβ [95].”
Features of Mitochondrial Dynamics in Different Brain Parts of Patients with Alzheimer’s Disease
Sukhorukov, V. S., Baranich, T. I., Velts, O. V., Воронков, Д. Н., Shcherbak, E. V., Lazarev, D. S., Kharlamov, D. A., & Raksha, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010107 · Cited by 1
Targeting innovative therapeutic approaches to the hallmarks of aging to combat Alzheimer’s disease
Izrael, M., & Frenkel, O. M. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00966 · Cited by 1
“Mitochondrial dysfunction, including reduced oxidative phosphorylation, altered dynamics, and excessive reactive oxygen species production, is evident early in AD and contributes to synaptic failure and cell death (Swerdlow, 2018).”
Wang, P., Wu, X., Sun, F., Zhang, H., Jiang, Y., Wang, Q., Ding, H., Zhou, Y., Liu, F., & Liu, H. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100452 · Cited by 1
“Mitochondrial dysfunction is a hallmark of AD [67,68], and recent finding suggests that impaired mitophagy contributes to synaptic dysfunction and cognitive deficits by increasing oxidative damage and cellular energy deficits, which in turn promote the accumulation of A β and Tau [69].”
Exercise mitigates Alzheimer’s disease by targeting ferroptosis driven by cellular senescence
Yu, Y., & Chen, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1742209 · Cited by 8
“These include progressive mitochondrial dysfunction (Swerdlow, 2018), chronic oxidative and metabolic stress (Liu et al., 2022a), persistent neuroinflammation (Leng and Edison, 2021), and impaired proteostasis, all of which synergistically compromise neuronal resilience and accelerate the…”
Dong, W., Yuan, Q., Wu, B., Gao, S., Zhang, Y., Pan, Y., Zhou, K. S., & Jiang, H. (2026) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2026.100780 · Cited by 2
“The “ mitochondrial cascade hypothesis ” posits that impaired mitochondrial metabolism may be an upstream driver of AD pathology [47,48].”
Ke, Z., Wang, B., & Liang, R. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424276 · Cited by 3
“A study conducted in H9C2 rat cardiomyocytes showed that irisin was still able to upregulate mRNA levels of cytochrome c oxidase subunit 4, a key gene involved in mitochondrial biogenesis, even under conditions in which PGC-1 α expression was suppressed.”
InfluentialDondi, M., Bianchi, E., Borghetti, P., Lecce, R. D., Gnudi, G., Guarnieri, C., Buffagni, V., Ravanetti, F., Saleri, R., & Corradi, A. (2026) · Veterinary Sciences · doi:10.3390/vetsci13030298 · Cited by 2
Wu, W., Wang, H., Zhang, L., Li, D., Chen, Y., Lin, B., Jiang, H., Meng, T., Zhu, Z., He, L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1811373 · Cited by 1
“The pathological mechanisms underlying AD involves a complex interplay of mechanisms, including mitochondrial dysfunction, neuroinflammation, and critically, persistent oxidative stress (Swerdlow, 2018; Butterfield and Halliwell, 2019; Gao et al., 2025).”
Bhasha, S., Chintada, V., Munikumar, M., Maddineni, J., Nagulavancha, R., Malempati, T., Gadda, S. S., Sankepally, K. K. R., & Pradeepkiran, J. A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103186 · Cited by 2
Offerdahl, J. E. V., & Mor, D. E. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1846384 · Cited by 1
“However, other studies suggest that misfolded tau and A β may instead drive mitochondrial dysfunction (Di Filippo et al., 2010; Swerdlow, 2018).”
Mitochondrial Dysfunction in Alzheimer’s Disease and Mitochondria-Targeted Therapeutics
Bisht, J., Rawat, P., Shin, A. C., & Hegde, V. (2026) · Cells · doi:10.3390/cells15110990 · Cited by 2
Targeting Mitochondria in Aging‐Related Diseases: Therapeutic Potential and Obstacles
Xiang, Z., Chen, Y., Liu, X., Lu, H., Yang, Y., Xing, L., Zhang, Y., Lang, C., Zhang, S., Zhao, S., et al. (2026) · MedComm · doi:10.1002/mco2.70790 · Cited by 4
Unveiling the pathogenesis and therapeutic strategies of Alzheimer’s disease through cuproptosis
Xu, S., Mu, J., Wang, Z., Yang, J., Tian, D., Shi, T., Lan, J., He, P., Hao, Z., Fu, Y., et al. (2026) · BioMetals · doi:10.1007/s10534-026-00835-5 · Cited by 1
“Currently, extensive research suggests that mitochondria may mediate, drive, or contribute to multiple pathological processes in AD (Swerdlow et al. 2018).”
Nanoparticles that target nonamyloid and nontau pathways in Alzheimer’s disease
Alavian, F., & Hajimohammadi, A. (2026) · Discover Nano · doi:10.1186/s11671-026-04747-8 · Cited by 1
“ER stress plays a significant role in the progression of AD, primarily through the accumulation of misfolded proteins, disruption of homeostasis, increased oxidative stress, and neuroinflammation, which result in neuronal dysfunction and cell death [86, 87].”
Kumar, N., Mir, P. A., Bhutia, G. T., Chaudhary, P., Kaur, G., Alam, Q., Pawar, S. D., & Gupta, S. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05983-w · Cited by 1
“In AD, neuronal mitochondria exhibit reduced OXPHOS, diminished membrane potential, and elevated ROS production associated with impaired complex I and IV activities [45, 46].”
Thelwell, J., & Johnson, A. J. (2026) · Neuroglia · doi:10.3390/neuroglia7030018 · Cited by 1
Jiang, L., Zhang, Z., Luo, X., Wu, H. W., 黄志纯, Wu, W., Xu, S., Pan, J., & Tan, Z. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124583 · Cited by 1
Selcan, A., Demirgan, S., Şengelen, A., Oran, D. S., Aksüt, Y., Yüzbaşioğlu, G., GÜRGEN, H. Ö., Gemici, E. K., & Gülçubuk, A. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103538 · Cited by 1
Godinho, W. D. N., Filho, F. S. L. V., Amaral, C. M. L., Guedes, M. I. F., de Serpa, G. L., Loureiro, A. C. C., Ceccatto, V. M., & Soares, P. M. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07397-5 · Cited by 1
Mitochondrial abnormalities in neurological disorders
Ferreira, A. F. F., Singulani, M. P., & de Britto, L. R. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822416-8.00012-9 · Cited by 1
Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides
Alberdi, E. M., Ruiz, A., Sánchez‐Gómez, M. V., Capetillo‐Zarate, E., & Matute, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821562-3.00003-4 · Cited by 2
Tong, X., Li, W., Liang, J.-H., Yang, Z., & Dai, S. (2022) · Gene · doi:10.1016/j.gene.2022.146501 · Cited by 1
Mitophagy Impairments as Culprit of Alzheimer’s Disease
Mani, S., Swargiary, G., Singh, M., & Rawal, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_5 · Cited by 1
Emerging Treatments for Alzheimer's Disease
Zhao, Z. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v54i.9778 · Cited by 2
STARRING ROLE OF MITOCHONDRIAL IMPAIRMENT IN ALZHEIMER’S DISEASE NEUROPATHOLOGY
Yousaf, A., Deeba, F., Younis, S., Iqbal, N., & Aslam, F. (2022) · THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS · doi:10.52700/jmmg.v3i2.70 · Cited by 1
Special Issue “Pathophysiology and Treatment of Alzheimer’s Disease”
Fessel, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116015 · Cited by 1
Walsh, M., Latham, A. S., Zhang, Q., Jacobs, R. A., Musci, R. V., LaRocca, T. J., Moreno, J. A., Santangelo, K. S., & Hamilton, K. L. (2024) · Acta Physiologica · doi:10.1111/apha.14185 · Cited by 1
“13,20 Assessing complex-specific respiration in addition to overall mitochondrial respiratory potential is pertinent in preclinical models.”
COVID-19 and Alzheimer's Disease: A Review of Mechanisms and Pathophysiology
Mohammadkhanizadeh, A., & Karimzadeh, F. (2021) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.9.2.151 · Cited by 1
Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases
Grivennikov, I. A., & Tarantul, V. Z. (2021) · Neurochemical Journal · doi:10.1134/s181971242104005x · Cited by 1
Wong-Guerra, M., Montano-Peguero, Y., Ramírez-Sánchez, J., Jiménez-Martín, J., Fonseca-Fonseca, L. A., Hernández-Enseñat, D., Nonose, Y., Valdés, O., Mondelo-Rodríguez, A., Ortiz-Miranda, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-163869/v1 · Cited by 1
Doppen, P. (2007) · Utrecht University Repository (Utrecht University) · Cited by 1
Stepanov, Y. V., Golovynska, I., Zhang, R., Golovynskyi, S., Stepanova, L. I., Gorbach, O. I., Dovbynchuk, T., Garmanchuk, L., Ohulchanskyy, T. Y., & Qu, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1377965/v1 · Cited by 1
Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Díaz, I., Brinton, R. D., & Mosconi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1723651/v1 · Cited by 1
Correction of mitochondrial dysfunction with cinnamic acids in experimental hypercytokinemia
Pozdnyakov, D. I. (2022) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2022-8-3-0-7 · Cited by 1
Fišar, Z., Hroudová, J., Zvěřová, M., Jirák, R., Vaněčková, M., & Raboch, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2402088/v1 · Cited by 1
Shang, Y., Cho, W. J., Munj, S. A., Jena, S. G., Arslanturk, S., Patil, S., Qi, X., & Jena, B. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.09.647859 · Cited by 1
Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer’s DiseasePreprint
Hawkinson, T. R., Liu, Z., Ribas, R. A., Medina, T., Nielsen, R. S., Clarke, H. A., Ma, X., Mueller, A. C., Plasencia, A. F., Shear, A. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.30.651461 · Cited by 1
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.